In course correction, AbbVie steers toward innovation with Genmab deal

AbbVie reaffirms its commitment to cancer, paying $750M up front for rights to a trio of Genmab bispecifics

AbbVie’s Genmab deal gives it a ticket to one of the hottest modality spaces, albeit as a latecomer.

The pharma gains bispecific antibodies to add to its ADCs and standard mAbs, extending its tool kit in cancer to cover the much-watched area of T cell engagers that can compete with CAR Ts.

The deal represents a renewed commitment to cancer -- and solid tumors in particular -- following a pair of Phase III failures, as well as a course correction after the $63 billion takeout of Allergan plc, which prioritized revenue over innovation. Still, the biopharma isn’t straying far from its lane of antibody-based drug development.

The deal also comes as AbbVie is aggressively pursuing ways to help it offset future generic competition for its top seller, Humira

Read the full 1271 word article

How to gain access

Continue reading with a
two-week free trial.